To explore the therapeutic potential of tpCD4+ T cells as APC, we tested whether tpCD4+ T-cell-mediated activation of naive CD8+ T cells confers protection from tumour formation in a murine model of malignant melanoma. This evidence concerns the gene CD8A and melanoma.